Etay Ziv, MD, PhD
Memorial Sloan Kettering Cancer Center
Research Project:
Reducing Risk of Local Recurrence After Ablation for Early-Stage Lung Cancer
Grant Awarded:
- Lung Cancer Discovery Award
Research Topics:
- biomarkers
- clinical research
- imaging radiology
- modeling
- surgery
Research Disease:
- lung cancer
Surgical removal of the tumor is the standard treatment for early-stage lung cancer. Lung ablation, a minimally invasive procedure that destroys tumor tissue by either heat or cooling, is an alternative for patients who are not surgical candidates. A major limitation for lung ablation is that there is no way to confirm whether tumor was completely eradicated. The success of lung ablation is determined by creating a large enough ablation area that extends a minimum margin beyond the tumor. However, identifying the extent of the ablation is challenging because of inflammation in the treatment area, which results in incomplete treatment and local recurrence (LR). We have developed computational tools to identify the extent of the treatment based on imaging done during the procedure, and to measure the margin of the ablation based on follow-up imaging. We plan to validate these tools to identify regions at high risk of LR during the procedure or on follow-up imaging. This will allow us to modify the treatment during the procedure, thereby reducing LR and improving outcomes.
Page last updated: October 7, 2024
Double Your Support Now
Your gift will have 2X the impact this COPD Awareness Month.
